Holen Sie sich die Stockscreener-App
9.97
0.50%
0.05
Handel nachbörslich:
10.00
0.03
+0.30%
Schlusskurs vom Vortag:
$9.92
Offen:
$9.93
24-Stunden-Volumen:
5.80M
Relative Volume:
1.38
Marktkapitalisierung:
$1.87B
Einnahmen:
$331.41M
Nettoeinkommen (Verlust:
$-226.54M
KGV:
-8.4492
EPS:
-1.18
Netto-Cashflow:
$-97.31M
1W Leistung:
+11.65%
1M Leistung:
+47.27%
6M Leistung:
+28.15%
1J Leistung:
+86.70%
1-Tages-Spanne:
$9.90
$10.39
1-Wochen-Bereich:
$9.59
$11.11
52-Wochen-Spanne:
$5.23
$11.11
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Vergleichen Sie BCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.97 | 1.87B | 331.41M | -226.54M | -97.31M | -1.18 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
Best Momentum Stocks to Buy for May 9th - Yahoo Finance
Mariner LLC Buys 3,224 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst targets $1B in global ORLADEYO revenue by 2029 amid 33-37% projected growth this year - MSN
Why BioCryst (BCRX) Might be Well Poised for a Surge - Yahoo Finance
What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
BioCryst at Citizens JMP: Orlodayo’s Market Growth and Pipeline Prospects - Investing.com
BioCryst at Citizens JMP: Orlodayo’s Market Growth and Pipeline Prospects By Investing.com - Investing.com UK
Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect? - Yahoo Finance
Biocryst seeks FDA OK of Orladeyo for HAE patients as young as 2 - Angioedema News
Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results - Yahoo Finance
Barclays Raises BioCryst Pharma (BCRX) Price Target to $11 | BCR - GuruFocus
Barclays Raises BioCryst Pharma (BCRX) Price Target to $11 | BCRX Stock News - GuruFocus
Barclays Raises Price Target for BioCryst (BCRX), Highlights Growth Prospects | BCRX Stock News - GuruFocus
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1 - MSN
BioCryst Pharmaceuticals’ SWOT analysis: stock outlook amid HAE market growth - Investing.com Nigeria
BioCryst Pharma (BCRX) Sees Price Target Boost from RBC Capital | BCRX Stock News - GuruFocus
BioCryst Pharma (BCRX) Price Target Raised by JP Morgan | BCRX Stock News - GuruFocus
BCRX Price Target Raised as BioCryst Shows Strong Fundamentals | - GuruFocus
BioCryst Pharma (BCRX) Maintains Buy Rating with $30 Price Targe - GuruFocus
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2025 Earnings Call Transcript - Insider Monkey
RBC Raises Price Target on BioCryst Pharmaceuticals to $13 From $11, Keeps Outperform Rating - marketscreener.com
BCRX Stock: BioCryst's Price Target Raised with Positive Revenue - GuruFocus
When (BCRX) Moves Investors should Listen - news.stocktradersdaily.com
Why These 10 Firms Soared on Monday - Insider Monkey
BCRX: Needham Raises Price Target for BioCryst Pharma to $17 | B - GuruFocus
Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday - Yahoo Finance
BioCryst stock target to $14 on Orladeyo sales, maintains Buy By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ... - Yahoo Finance
BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highli - GuruFocus
Earnings call transcript: BioCryst’s Q1 2025 revenue and stock surge By Investing.com - Investing.com Nigeria
BioCryst (BCRX) Surges with ORLADEYO Revenue and Debt Reduction Efforts - GuruFocus
BioCryst Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks
BioCryst Shares Surge To 16-Month High On Strong Q1 Results: Retail Sentiment Turns Extremely Bullish - MSN
BioCryst Pharmaceuticals (BCRX) Boosts Revenue Guidance on Stron - GuruFocus
BioCryst Pharmaceuticals Soars 23% In One SessionHere's Why It Surprised Investors - Benzinga
BioCryst Pharmaceuticals (BCRX) Boosts Revenue Guidance on Strong ORLADEYO Sales - GuruFocus
Top Midday Gainers - marketscreener.com
BioCryst: Strong Opportunity For A Double With A Proven Therapy (BCRX) - Seeking Alpha
BioCryst Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Crude Oil Falls Over 2%; ISM Services PMI Rises In April - Benzinga
BioCryst Pharmaceuticals surges 2% on strong Q1 results, raised outlook By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals (BCRX) Surges on Q1 Earnings Beat: What Traders Need to Know - RagingBull
BioCryst Pharmaceuticals (BCRX) Boosts Revenue Forecast Amid Strong Q1 Results - GuruFocus
BioCryst Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha
BioCryst stock jumps on raised guidance, strong Q1 report - Seeking Alpha
Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
BioCryst Hikes on Q1 Figures - Baystreet.ca
Earnings call transcript: BioCryst’s Q1 2025 revenue and stock surge - Investing.com
BioCryst Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BioCryst Q1 2025 slides: ORLADEYO sales surge, guidance raised By Investing.com - Investing.com Canada
BioCryst Pharma Stock Soars 10% Pre-Market On Upbeat Q1 Earnings, Improved Full Year Guidance: Retail’s Pleased - MSN
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
1.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):